The Way I See ItAfter examining the clinical trial results for efficacy gains, it's not obvious why FDA is asking for more partial clinical trial results .
However, it's a known fact that the FDA will respond more favorably and with expeditious speed for a drug submitted by a US pharma than a foreign pharma.
This might be the case here.
Looking at outcome scenarios , there isn't much risk in buying in now.
TST have about $0.17 and $0.19 in cash and liquid investments and no debt.
If the drug is a current failure, we are very well off with all that cash.
I doubt this scenario will be the outcome
If management can convince FDA that little or no further research is necessary, the share price will pop big time, as sales implications are substantial .
Both scenarios are risk averse.
Further, it seems obvious that forced loquidation by Anon is now nearing its end.
That too will be beneficial for holders